ISPOR - EE465 Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy

Full Text

EE465 Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy

Abstract

Authors

F Piccolo J Tosh S De Boisvilliers S Patel V Patel

Back to Volume 25, Supplemental Issue 12S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now